期刊文献+

PD-1和TIM-3在胃癌病人免疫组织CD3^+T细胞中的表达分析 被引量:10

Increased expression of PD-1 and TIM-3 on CD3^+T cells from gastric cancer patients
下载PDF
导出
摘要 目的探讨在胃癌病人外周血、癌旁组织和肿瘤组织中T细胞上PD-1和TIM-3的表达状况及意义。方法应用流式细胞术检测来自胃癌病人外周血、癌旁组织和肿瘤组织及正常供体外周血的CD3+T细胞,分析PD-1和TIM-3的表达水平。结果PD-1和TIM-3在胃癌病人T细胞上表达水平明显高于正常供体。相比胃癌病人外周血,肿瘤组织TIL的PD-1和TIM-3表达水平更高。另外,PD-1和TIM-3的表达水平与胃癌病人的年龄和肿瘤大小存在相关性。通过阻断PD-1和TIM-3信号通路可以增强TIL抗肿瘤细胞毒性。结论 PD-1和TIM-3可能与胃癌的恶变有关。单克隆抗体靶向阻断PD-1和TIM-3通路有希望成为胃癌免疫治疗的新方法。 To determine the expression of PD-1 and TIM-3 on T cells in tumor tissue,adjacent gastric mucosa and PBMC from patients with gastric cancer,flow cytometry was used to test the expression of PD-1 and TIM3 on CD3+T cells from tumor tissue,adjacent gastric mucosa and PBMC,as well as from normal donor PBMC.The levels of PD-1 and TIM-3 expressed on T cells from gastric cancer patients were significantly higher than those of normal donors.The percentages of tumor infiltrating lymphocytes(TILs) expressing PD-1 and TIM-3 were significantly higher than that in PBMC of gastric cancer patients.Moreover,the expression of PD-1 and TIM-3 was associated with the age and tumor size of patients.TILs cytotoxicity against tumor was enhanced when blocking PD-1 and TIM-3 pathways.Therefore,our results indicate that PD-1 and TIM-3 may play a pivotal role in the progression of gastric cancer and blockade of PD-1 and TIM-3 pathways using monoclonal antibodies could be a promising immunotherapy for gastric cancer.
出处 《免疫学杂志》 CAS CSCD 北大核心 2014年第10期902-905,共4页 Immunological Journal
基金 国家自然科学基金(31471283 81272536) 江苏省科技支撑社会发展项目(BE2011682)
关键词 胃癌 PD-1 TIM-3 共抑制因子 Gastric cancer PD-1 TIM-3 Co-inhibitory receptor
  • 相关文献

参考文献14

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
  • 2陈娜,庄园,王婷婷,彭六生,程平,李文华,赵永亮,余佩武,邹全明.肥大细胞在胃癌患者中分布及其免疫抑制作用的研究[J].免疫学杂志,2014,30(1):1-5. 被引量:3
  • 3Smith Garvin JE, Koretzky GA, Jordan MS. T cell activation [J]. Annu Rev lmmunol, 2009, 27: 591-619.
  • 4Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Caneer, 2012, 12(4): 252- 264.
  • 5Nirschl C J, Drake CG. Molecular pathways: co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy[J]. Clin Cancer Res, 2013, 19(18): 4917--4924.
  • 6Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients[J]. J Exp Med, 2010. 207(10): 2175-2186.
  • 7Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-I pathways to reverse T cell exhaustion and restore anti-tumor immunity[J]. J Exp Med, 2010, 207(10): 2187- 2194.
  • 8Ngiow SF, wm Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and supprsses established tumors[J]. Cancer Res, 2011, 71(10): 3540-3551.
  • 9Sun J, Xu K, Wu C, etal. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies[J]. Tissue Antigens, 2007, 69(1): 19-27.
  • 10Saito H, Kuroda H, Matsunaga T, et al. Increased PD-1 expression on CD4 + and CD8 + T cells is involved in immune evasion in gastric cancer[J]. J Surg Oncol, 2013, 107(5): 517-522.

二级参考文献19

  • 1Shi-YunTan,YanFan,He-ShengLuo,Zhi-XiangShen,YiGuo,Liang-JiaZhao.Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer[J].World Journal of Gastroenterology,2005,11(8):1210-1214. 被引量:19
  • 2Betts G, Jones E, Junaid S, et al. Suppression of tumour- specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer [J]. Gut, 2012, 61($): 1163-1171.
  • 3Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer[J]. Eur J Cancer, 2005, 41(17): 2645-2654.
  • 4Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours [M]. 7th Edition. John Wiley & Sons, 2009.
  • 5Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer [J]. J Leukoe Biol, 2008, 84(4): 981-987.
  • 6Galon J, Costes A, Sanchez Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313 (5795): 1960-1964.
  • 7Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens[J]. Nat Med, 1998, 4(7): 844-847.
  • 8Abutaily AS, Addis B J, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies[J]. J Clin Pathol, 2002, 55 (9): 662-668.
  • 9Lee S J, Lira HJ, Choi YH, et al. The clinical significance of tumor-infiltrating lymphocytes and microscopic satellites in acral melanoma in a korean population[J]. Ann Dermatol, 2013, 25(1): 61-66.
  • 10Scurr M, Gallimore A, Godkin A. T cell subsets and colorectal cancer: discerning the good from the bad[J]. Cell Immunol, 2012, 279(1): 21-24.

共引文献6

同被引文献69

  • 1An-Hui Wang,Yuan Liu,Bo Wang,Yi-Xuan He,Ye-Xian Fang,Yong-Ping Yan.Epidemiological studies of esophageal cancer in the era of genome-wide association studies[J].World Journal of Gastrointestinal Pathophysiology,2014,5(3):335-343. 被引量:15
  • 2黄迪君,王再谟,周志昆,金荣疆,高虹,万大凤,张安仁.麦粒灸加叩刺拔罐法治疗类风湿性关节炎120例[J].成都中医药大学学报,1996,19(1):17-19. 被引量:18
  • 3Dhir S, Slatter M, Skinner R. Recent advances in the management of graft-versus-host disease[J]. Arch Dis Child, 2014, 99(12): 1150-1157.
  • 4Hall BM. Cells mediating allograft rejection [J]. Transplantation, 1991, 51(6): I141-I151.
  • 5Boenisch O, D'Addio F, Watanabe T, et al. TIM-3: a novel regulatory molecule of alloimmune activation[J]. J Immunol, 2010, 185(10): 5806-5819.
  • 6Su EW, Lin JY, Kane LP. TIM-1 and TIM-3 proteins inimmune regulation[J]. Cytokine, 2008, 44(1): 9-13.
  • 7Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance [J]. Nat Immunol, 2003, 4(11): 1102-1110.
  • 8Sanchez Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance [J]. Nat Immunol, 2003, 4(11): 1093-1101.
  • 9Nakae S, Iwakura Y, Suto H, et al. Phenotypic differences between Thl and Thl7 cells and negative regulation of Thl cell differentiation by IL-17[J]. J Leukoc Biol, 2007, 81(5): 1258-1268.
  • 10Frisancho Kiss S, Nyland JF, Davis SE, et al. T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity [J]. J Immunol, 2006, 176(11): 6411-6415.

引证文献10

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部